Key points are not available for this paper at this time.
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)
Building similarity graph...
Analyzing shared references across papers
Loading...
Keith T. Flaherty
Igor Puzanov
Kevin B. Kim
New England Journal of Medicine
University of Pennsylvania
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Flaherty et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d6bfdbfca0359822aa831e — DOI: https://doi.org/10.1056/nejmoa1002011
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: